Literature DB >> 18372773

[Combined use of pattern electroretinography and pattern visual evoked potentials in neuroophthalmological practice].

Krisztina Benedek1, Andrea Pálffy, Krisztina Bencsik, Imre Fejes, Cecília Rajda, Gábor Tuboly, Péter Liszli.   

Abstract

OBJECTIVE: To survey the role of pattern electroretinography (PERG) and pattern visual evoked potentials (VEPs) in the process of clinical evaluation of neuro-ophthalmological cases. The study is illustrated with the electrophysiological findings of 231 patients sent to our laboratory in 2005 because of the suspicion of damage in the optic pathway.
METHODS: The RETIport program of the ROLAND equipment (Wiesbaden-Germany) was used to record PERGs and VEPs. The recordings were done according to the recommendations of the International Society for Clinical Electrophysiology of Vision.
RESULTS: The combined application of PERG and VEP provided useful data on the retino-cortical conduction time and hence demyelinisation. The comparison of the N35/P50 and P50/N90 amplitudes of the PERG recordings greatly promoted the diagnostic procedure.
CONCLUSIONS: The combined application of PERG and VEP methods is recommended in the assessment of optic nerve function of neuro-ophthalmological patients.

Entities:  

Mesh:

Year:  2008        PMID: 18372773

Source DB:  PubMed          Journal:  Ideggyogy Sz        ISSN: 0019-1442            Impact factor:   0.427


  2 in total

1.  Efficacy of N95 amplitude of pattern electroretinogram measured from baseline to N95 trough in the traumatic optic neuropathy.

Authors:  Kun Hae Kim; Ungsoo Samuel Kim
Journal:  Jpn J Ophthalmol       Date:  2019-03-08       Impact factor: 2.447

2.  Migration of pre-induced human peripheral blood mononuclear cells from the transplanted to contralateral eye in mice.

Authors:  Jianfa Huang; Bikun Xian; Yuting Peng; Baozhu Zeng; Weihua Li; Zhiquan Li; Yaojue Xie; Minglei Zhao; Hening Zhang; Minyi Zhou; Huan Yu; Peixin Wu; Xing Liu; Bing Huang
Journal:  Stem Cell Res Ther       Date:  2021-03-10       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.